Existing and Future Drugs for the Treatment of the Dark Side of Addiction
The DOI matches its Crossref record; 146 of the 147 references it cites were found in a registry or an index.
Abstract
The identification of a heuristic framework for the stages of the addiction cycle that are linked to neurocircuitry changes in pathophysiology includes the binge/intoxication stage, the withdrawal/negative affect stage, and the preoccupation/anticipation (craving) stage, which represent neuroadaptations in three neurocircuits (basal ganglia, extended amygdala, and frontal cortex, respectively). The identification of excellent and validated animal models, the development of human laboratory models, and an enormous surge in our understanding of neurocircuitry and neuropharmacological mechanisms have provided a revisionist view of addiction that emphasizes the loss of brain reward function and gain of stress function that drive negative reinforcement (the dark side of addiction) as a key to compulsive drug seeking. Reversing the dark side of addiction not only explains much of the existing successful pharmacotherapies for addiction but also points to vast new opportunities for future medications to alleviate this major source of human suffering.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Our contention is that the field of the neurobiology of addiction has excellent and validated animal models and well developed clinical models that, combined with the neurocircuitry analysis herein, will provide a unique approach to medication development that emphasises excessive incentive salience, the loss of brain reward function, and the gain of stress function that drive negative reinfor”
From Neurobiology of addiction: a neurocircuitry analysis (2016) · cites this paper as [13]
Citations
Cites
Koob, G. F., & Volkow, N. D. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.110 · Cited by 5,340
Self-citationA New Initiative on Precision Medicine
Collins, F. S., & Varmus, H. (2015) · New England Journal of Medicine · doi:10.1056/nejmp1500523 · Cited by 5,202
Martin, W. R., Eades, C. G., Thompson, J. A., Huppler, R. E., & Gilbert, P. E. (1976) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)30536-7 · Cited by 2,992
Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor
Meunier, J.-C., Mollereau, C., Toll, L., Suaudeau, C., Moisand, C., Alvinerie, P., Butour, J.-L., Guillemot, J.-C., Ferrara, P., Monsarrat, B., et al. (1995) · Nature · doi:10.1038/377532a0 · Cited by 1,912
Orphanin FQ: A Neuropeptide That Activates an Opioidlike G Protein-Coupled Receptor
Reinscheid, R. K., Nothacker, H.-P., Bourson, A., Ardati, A., Henningsen, R. A., Bunzow, J. R., Grandy, D. K., Langen, H., Monsma, F. J., & Civelli, O. (1995) · Science · doi:10.1126/science.270.5237.792 · Cited by 1,821
The reinstatement model of drug relapse: history, methodology and major findings
Shaham, Y., Shalev, U., Lu, L., de Wit, H., & Stewart, J. (2003) · Psychopharmacology · doi:10.1007/s00213-002-1224-x · Cited by 1,615
Addiction and the brain antireward system
Koob, G. F., & Le Moal, M. (2008) · Annual Review of Psychology · doi:10.1146/annurev.psych.59.103006.093548 · Cited by 1,457
Self-citationMultiple dopamine functions at different time courses
Schultz, W. (2007) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.28.061604.135722 · Cited by 1,415
A Role for Brain Stress Systems in Addiction
Koob, G. F. (2008) · Neuron · doi:10.1016/j.neuron.2008.06.012 · Cited by 1,056
Self-citation
Research works printed but not linked: 1
- Qiang M, 2014, Int. J. Neuropsychopharmacol., 18, 1
Cited by
Neurobiology of addiction: a neurocircuitry analysis
Koob, G. F., & Volkow, N. D. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)00104-8 · Cited by 3,698
Self-citationOpioid receptors: drivers to addiction?
Darcq, E., & Kieffer, B. L. (2018) · Nature Reviews Neuroscience · doi:10.1038/s41583-018-0028-x · Cited by 352
Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development
Koob, G. F. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000083 · Cited by 337
“For further details of these polymorphisms and their associations with hyperkatifeia, see Koob and Mason (2016) and Spierling and Zorrilla (2017).”
BackgroundSelf-citationCannabis Addiction and the Brain: a Review
Zehra, A., Burns, J., Liu, C. K., Manza, P., Wiers, C. E., Volkow, N. D., & Wang, G.-J. (2018) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-018-9782-9 · Cited by 249
Neuroimmune signaling in alcohol use disorder
Erickson, E. K., Grantham, E. K., Warden, A. S., & Harris, R. A. (2019) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2018.12.007 · Cited by 223
Metadata
- Authors
- Koob, G. F., & Mason, B. J.
- Affiliations
- Scripps Research Institute (US)
- ORCID
- Koob, George F.
- Venue
- Annual Review of Pharmacology and Toxicology
- Publisher
- Annual Reviews
- Published
- 2016-01-06
- Volume
- 56
- Issue
- 1
- Pages
- 299-322
- ISSN
- 0362-1642 (ISSN-L)
- 1545-4304
- OpenAlex
- W1829470622
- Cited by
- 121
- References
- 147
- Citations by year
- 2026: 6 · 2025: 7 · 2024: 10 · 2023: 3 · 2022: 7 · 2021: 7 · 2020: 18 · 2019: 18 · 2018: 13 · 2017: 17 · 2016: 14
- FWCI
- 1.77
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Annual Review of Pharmacology and Toxicology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Alcohol Abuse and Alcoholism (AA012602, AA023152, R01AA023152, R01AA012602)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Social Sciences › Psychology › Clinical Psychology › Gambling Behavior and Treatments
- Keywords
- negative reinforcement, addiction pharmacotherapy, neural adaptation, basal ganglia, extended amygdala, frontal cortex, drug craving, withdrawal, compulsive drug seeking, stress function, animal models of addiction
- MeSH terms
- Animals, Pharmaceutical Preparations, Humans, Behavior, Addictive, Substance-Related Disorders, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Existing and Future Drugs for the Treatment of the Dark Side of Addiction. https://app.cochat.ai/papers/10.1146/annurev-pharmtox-010715-103143
- The paper
- Koob, G. F., & Mason, B. J. (2016). Existing and Future Drugs for the Treatment of the Dark Side of Addiction. Annual Review of Pharmacology and Toxicology. https://doi.org/10.1146/annurev-pharmtox-010715-103143
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.